
Vertex Pharmaceuticals has re-upped its ties with sequencing specialist Genomics in a deal worth up to $220 million, signing on for an extra four years on top of the eight the companies have already worked together.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks

